Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.22
AMRI's Cash to Debt is ranked lower than
92% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AMRI: 0.22 )
Ranked among companies with meaningful Cash to Debt only.
AMRI' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 5.22 Max: No Debt
Current: 0.22
Equity to Asset 0.35
AMRI's Equity to Asset is ranked lower than
80% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMRI: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
AMRI' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.82 Max: 0.96
Current: 0.35
0.35
0.96
Interest Coverage 0.82
AMRI's Interest Coverage is ranked lower than
99% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 0.82 )
Ranked among companies with meaningful Interest Coverage only.
AMRI' s Interest Coverage Range Over the Past 10 Years
Min: 1.52  Med: 13.31 Max: 52.66
Current: 0.82
1.52
52.66
F-Score: 3
Z-Score: 1.56
M-Score: -2.50
WACC vs ROIC
9.85%
49.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 2.85
AMRI's Operating margin (%) is ranked higher than
71% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. AMRI: 2.85 )
Ranked among companies with meaningful Operating margin (%) only.
AMRI' s Operating margin (%) Range Over the Past 10 Years
Min: -36.35  Med: 1.19 Max: 12.8
Current: 2.85
-36.35
12.8
Net-margin (%) -1.64
AMRI's Net-margin (%) is ranked higher than
68% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. AMRI: -1.64 )
Ranked among companies with meaningful Net-margin (%) only.
AMRI' s Net-margin (%) Range Over the Past 10 Years
Min: -31.74  Med: 0.01 Max: 8.97
Current: -1.64
-31.74
8.97
ROE (%) -2.35
AMRI's ROE (%) is ranked higher than
73% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AMRI: -2.35 )
Ranked among companies with meaningful ROE (%) only.
AMRI' s ROE (%) Range Over the Past 10 Years
Min: -22.52  Med: -0.34 Max: 6.22
Current: -2.35
-22.52
6.22
ROA (%) -0.98
AMRI's ROA (%) is ranked higher than
75% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AMRI: -0.98 )
Ranked among companies with meaningful ROA (%) only.
AMRI' s ROA (%) Range Over the Past 10 Years
Min: -17.99  Med: -0.05 Max: 5.29
Current: -0.98
-17.99
5.29
ROC (Joel Greenblatt) (%) 4.27
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AMRI: 4.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -35.54  Med: 2.14 Max: 13.92
Current: 4.27
-35.54
13.92
Revenue Growth (3Y)(%) 8.20
AMRI's Revenue Growth (3Y)(%) is ranked higher than
61% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMRI: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMRI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.5  Med: 7.75 Max: 78.2
Current: 8.2
-1.5
78.2
EPS Growth (3Y)(%) -54.10
AMRI's EPS Growth (3Y)(%) is ranked lower than
94% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AMRI: -54.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMRI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.1  Med: -8.20 Max: 37.3
Current: -54.1
-58.1
37.3
» AMRI's 10-Y Financials

Financials (Next Earnings Date: 2016-02-17)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AMRI Guru Trades in Q1 2015

Steven Cohen 233,100 sh (New)
Chuck Royce 1,291,216 sh (+4.47%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones 14,900 sh (-38.43%)
Jim Simons 62,242 sh (-50.66%)
» More
Q2 2015

AMRI Guru Trades in Q2 2015

Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 1,219,316 sh (-5.57%)
Steven Cohen 184,900 sh (-20.68%)
Jim Simons 27,324 sh (-56.10%)
» More
Q3 2015

AMRI Guru Trades in Q3 2015

Ken Fisher 170,876 sh (New)
Paul Tudor Jones 26,557 sh (New)
Jim Simons 110,881 sh (+305.80%)
Murray Stahl 56,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 1,091,316 sh (-10.50%)
» More
Q4 2015

AMRI Guru Trades in Q4 2015

Jim Simons 226,292 sh (+104.09%)
Ken Fisher 203,450 sh (+19.06%)
Murray Stahl 56,000 sh (unchged)
Chuck Royce 986,215 sh (-9.63%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 13.70
AMRI's Forward P/E is ranked higher than
61% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. AMRI: 13.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.87
AMRI's P/B is ranked higher than
67% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. AMRI: 1.87 )
Ranked among companies with meaningful P/B only.
AMRI' s P/B Range Over the Past 10 Years
Min: 0.28  Med: 1.09 Max: 3.08
Current: 1.87
0.28
3.08
P/S 1.36
AMRI's P/S is ranked higher than
93% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. AMRI: 1.36 )
Ranked among companies with meaningful P/S only.
AMRI' s P/S Range Over the Past 10 Years
Min: 0.31  Med: 1.66 Max: 2.93
Current: 1.36
0.31
2.93
PFCF 29.95
AMRI's PFCF is ranked higher than
50% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 30.10 vs. AMRI: 29.95 )
Ranked among companies with meaningful PFCF only.
AMRI' s PFCF Range Over the Past 10 Years
Min: 11.16  Med: 30.98 Max: 1757
Current: 29.95
11.16
1757
POCF 14.19
AMRI's POCF is ranked higher than
72% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. AMRI: 14.19 )
Ranked among companies with meaningful POCF only.
AMRI' s POCF Range Over the Past 10 Years
Min: 4.9  Med: 14.17 Max: 283.33
Current: 14.19
4.9
283.33
EV-to-EBIT 67.21
AMRI's EV-to-EBIT is ranked lower than
86% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. AMRI: 67.21 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRI' s EV-to-EBIT Range Over the Past 10 Years
Min: -90.5  Med: 15.15 Max: 455
Current: 67.21
-90.5
455
EV-to-EBITDA 22.70
AMRI's EV-to-EBITDA is ranked lower than
64% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. AMRI: 22.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.2  Med: 8.70 Max: 41.5
Current: 22.7
-40.2
41.5
Current Ratio 3.06
AMRI's Current Ratio is ranked lower than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AMRI: 3.06 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s Current Ratio Range Over the Past 10 Years
Min: 2.45  Med: 5.59 Max: 17.83
Current: 3.06
2.45
17.83
Quick Ratio 2.00
AMRI's Quick Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AMRI: 2.00 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s Quick Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.87 Max: 17.25
Current: 2
1.84
17.25
Days Inventory 88.06
AMRI's Days Inventory is ranked higher than
64% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. AMRI: 88.06 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s Days Inventory Range Over the Past 10 Years
Min: 57.53  Med: 63.97 Max: 102.1
Current: 88.06
57.53
102.1
Days Sales Outstanding 88.90
AMRI's Days Sales Outstanding is ranked lower than
65% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. AMRI: 88.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.89  Med: 60.86 Max: 94.55
Current: 88.9
43.89
94.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.67
AMRI's Price/Tangible Book is ranked lower than
54% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. AMRI: 9.67 )
Ranked among companies with meaningful Price/Tangible Book only.
AMRI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.39  Med: 1.66 Max: 16.72
Current: 9.67
0.39
16.72
Price/Projected FCF 2.05
AMRI's Price/Projected FCF is ranked higher than
65% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. AMRI: 2.05 )
Ranked among companies with meaningful Price/Projected FCF only.
AMRI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.4  Med: 0.84 Max: 3.31
Current: 2.05
0.4
3.31
Price/Median PS Value 0.84
AMRI's Price/Median PS Value is ranked higher than
53% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. AMRI: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.24 Max: 25.43
Current: 0.84
0.23
25.43
Price/Peter Lynch Fair Value 5.56
AMRI's Price/Peter Lynch Fair Value is ranked lower than
94% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 1.73 vs. AMRI: 5.56 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMRI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.74  Med: 2.08 Max: 80.81
Current: 5.56
0.74
80.81
Earnings Yield (Greenblatt) (%) 1.55
AMRI's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AMRI: 1.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMRI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 4.10 Max: 16.5
Current: 1.55
0.2
16.5
Forward Rate of Return (Yacktman) (%) 17.69
AMRI's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. AMRI: 17.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMRI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -16.6  Med: 0.20 Max: 21.1
Current: 17.69
-16.6
21.1

More Statistics

Revenue(Mil) $363
EPS $ -0.18
Beta1.37
Short Percentage of Float23.03%
52-Week Range $14.75 - 22.48
Shares Outstanding(Mil)35.50

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 411 501
EPS($) 0.76 1.12
EPS without NRI($) 0.76 1.12

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany,
Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 

More From Other Websites
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change... Feb 10 2016
AMRI to Announce Fourth Quarter and Full Year 2015 Results Feb 09 2016
NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture... Feb 08 2016
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers,... Feb 05 2016
AMRI Appoints Anthony J. Maddaluna to Board of Directors Feb 04 2016
AMRI Announces Executive Hire to Lead Active Pharmaceutical Ingredients Business Jan 20 2016
AMRI partners with Center for Nanomedicine Research on co-marketing deal Jan 14 2016
AMRI and NYCNMR Form Collaborative Agreement Jan 14 2016
AMRI and NYCNMR Form Collaborative Agreement Jan 14 2016
AMRI Announces 3-Year Extension of Insourcing Contract Jan 12 2016
Eagle Pharmaceuticals and AMRI Announce Agreement to Jointly Develop, Manufacture and Commercialize... Jan 11 2016
AMRI Announces First Product Approval Out of its Massachusetts Aseptic Fill Finish Site Jan 11 2016
AMRI Date and Time Change for J.P. Morgan Healthcare Conference Presentation Jan 10 2016
Albany Molecular Research, Icagen Announce New Agreement That Combines Both Companies' Assets Jan 07 2016
AMRI and Icagen Ink Collaboration Agreement Jan 07 2016
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
AMRI CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 21 2015
Albany Molecular Research, Inc. -- Moody's: AMRI's acquisition of Whitehouse Labs is credit positive Dec 17 2015
Albany Molecular Research, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK